Ireland-based Endo International plc (OTC:ENDPQ), a specialty pharmaceutical company, announced on Monday that one of its operating companies, Par Pharmaceutical, Inc, has commenced shipping of the authorised generic (AG) version of Merck's Noxafil (posaconazole) 200mg/5mL oral suspension in the United States.
Endo Ventures Limited, a subsidiary of Endo, has signed an exclusive US supply and distribution agreement with a subsidiary of Merck & Co., Inc. of Rahway, New Jersey. The distribution agreement is intended to enable Par Pharmaceutical to introduce and distribute an authorised generic version of the product. The contract also included the authorised generic version of Noxafil delayed-release tablets, 100 mg, which was launched in 2019.
The product is a registered trademark of Merck Sharp & Dohme LLC.
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US